Fierce Pharma released an article titled, "Valisure links 'unstable' Zantac and its ilk to carcinogen buildup, cancer risk." This article highlights the global recalls that resulted from our detection of high levels of a carcinogen in Zantac and its generic copycats.

View the full article via Fierce Pharma here.

Fierce Pharma released an article titled, "Valisure links 'unstable' Zantac and its ilk to carcinogen buildup, cancer risk." This article highlights the global recalls that resulted from our detection of high levels of a carcinogen in Zantac and its generic copycats.

View the full article via Fierce Pharma here.